(Q36861645)

16 August 2017

1 reference

title

Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes (English)

1 reference

methicillin-resistant Staphylococcus aureus

16 August 2017

0 references

vancomycin

1 reference

ChEBI release 2020-05-28

ChEBI ID

28001

Staphylococcus aureus

object named as

Staphylococcus aureus

1 reference

Thomas P Lodise

1

1 reference

PubMed ID

17594206

16 August 2017

Peggy S McKinnon

series ordinal

2

1 reference

PubMed ID

17594206

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

27

1 reference

16 August 2017

7

1 reference

16 August 2017

1001-1012

1 reference

Nosocomial infection update

16 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Resistance patterns among nosocomial pathogens: trends over the past few years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The crisis in antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Clinical identifiers of complicated Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Prediction Model to Identify Patients WithStaphylococcus aureusBacteremia at Risk for Methicillin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Is Methicillin-Resistant Staphylococcus aureus More Virulent than Methicillin-Susceptible S. aureus? A Comparative Cohort Study of British Patients with Nosocomial Infection and Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Community-associated methicillin-resistant Staphylococcus aureus: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Recurring methicillin-resistant Staphylococcus aureus infections in a football team

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

A clone of methicillin-resistant Staphylococcus aureus among professional football players.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Methicillin-resistant Staphylococcus aureus infection in the Texas prison system

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Increasing Prevalence of Methicillin-Resistant Staphylococcus aureus Infection in California Jails

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Molecular characteristics of nosocomial and Native American community-associated methicillin-resistant Staphylococcus aureus clones from rural Wisconsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Three-year surveillance of community-acquired Staphylococcus aureus infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Current and emerging serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The economic impact of Staphylococcus aureus infection in New York City hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The impact of antimicrobial resistance on health and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Economic impact of the community-acquired methicillin-resistant Staphylococcus aureus epidemic on the Driscoll Children's Health Plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Safety of patients isolated for infection control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Cost perspectives for outpatient intravenous antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.7.1001

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.7.1001

1 reference

16 August 2017

1 reference

PubMed ID

17594206